LRMR vs VYGR
LRMR: Larimar Therapeutics is developing a novel cell-penetrating peptide platform to treat rare, genetically driven diseases, with a lead program targeting the underlying protein deficiency in Friedreich's ataxia. VYGR: A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while advancing early-stage clinical programs.
Side-by-side fundamentals
| Metric | LRMR | VYGR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.02 | $3.10 | |
| Market cap as of 2026-07-23 | $418M | $187M | |
| PEG as of 2026-07-23 | -0.05 | -0.04 | LRMR lower |
| Net margin as of 2026-07-23 | n/a | -319.6% | |
| Operating margin as of 2026-07-23 | n/a | -349.2% | |
| ROE as of 2026-07-23 | -134.1% | -56.0% | VYGR higher |
| ROA as of 2026-07-23 | -96.0% | -43.1% | VYGR higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -45.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.76 | 1.31 | |
| 1-year return as of 2026-07-22 close | +18.9% | -1.9% | LRMR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.